Sanofi to Acquire Dren Bio’s Bispecific Antibody DR-0201 for ~$1.9B
Shots:
- Sanofi has entered into a definitive agreement with Dren Bio to acquire DR-0201, expanding its immunology pipeline
- As per the deal, Dren Bio will receive $600M upfront & ~$1.3B in development & launch milestones while continuing to operate independently to advance its pipeline of antibody therapeutics targeting pathogenic cells & other disease-causing agents; closing expected in Q2’25
- DR-0201 (CD20-directed bsAb) is being evaluated in 2 ongoing P-I studies, demonstrating substantial B-cell depletion in both non-clinical & clinical settings
Ref: Globenewswire | Image: Dren Bio
Related News:- Regeneron and Sanofi Report the US FDA’s sBLA Acceptance for Dupixent to Treat Bullous Pemphigoid (BP)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
